Nicola Silvestris Selected Research

Immune Checkpoint Proteins

5/2022	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.
5/2021	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
4/2021	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment.
1/2021	A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology.
1/2021	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.
4/2019	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicola Silvestris Research Topics

Disease

109	Neoplasms (Cancer) 07/2022 - 09/2001
28	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 01/2009
19	Breast Neoplasms (Breast Cancer) 05/2022 - 09/2001
17	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 04/2013
15	Pancreatic Neoplasms (Pancreatic Cancer) 06/2022 - 06/2013
15	Neoplasm Metastasis (Metastasis) 06/2022 - 06/2012
11	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2003
10	Adenocarcinoma 06/2022 - 09/2015
9	COVID-19 01/2022 - 01/2020
8	Melanoma (Melanoma, Malignant) 01/2021 - 04/2011
6	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2022 - 12/2015
6	Triple Negative Breast Neoplasms 06/2021 - 04/2012
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2019 - 12/2005
5	Inflammation (Inflammations) 06/2022 - 10/2016
5	Head and Neck Neoplasms (Head and Neck Cancer) 07/2020 - 02/2010
5	Neutropenia 02/2020 - 01/2003
5	Carcinogenesis 09/2015 - 01/2011
4	Microsatellite Instability 06/2022 - 12/2011
4	Lung Neoplasms (Lung Cancer) 04/2022 - 06/2018
4	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 04/2011
3	Infections 08/2021 - 01/2020
3	Glioma (Gliomas) 02/2021 - 01/2021
3	Primitive Neuroectodermal Tumors (PNET) 01/2021 - 07/2017
3	Multiple Myeloma 02/2020 - 04/2011
3	Hypertension (High Blood Pressure) 12/2017 - 09/2012
3	Colonic Neoplasms (Colon Cancer) 08/2017 - 01/2009
2	Lymphoma (Lymphomas) 05/2022 - 09/2014
2	Virus Diseases (Viral Diseases) 02/2022 - 08/2021
2	Fatigue 01/2022 - 11/2007
2	Carcinoma (Carcinomatosis) 11/2021 - 03/2005
2	Cholangiocarcinoma 01/2021 - 02/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2020 - 05/2020
2	Circulating Neoplastic Cells 05/2020 - 02/2013
2	Anemia 01/2020 - 11/2007
2	Thrombosis (Thrombus) 10/2019 - 03/2005

Drug/Important Bio-Agent (IBA)

16	Biological ProductsIBA 05/2022 - 01/2005
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2010
15	Immune Checkpoint InhibitorsIBA 05/2022 - 04/2019
15	MicroRNAs (MicroRNA)IBA 04/2022 - 09/2013
15	Proteins (Proteins, Gene)FDA Link 04/2022 - 06/2012
15	Sorafenib (BAY 43-9006)FDA Link 02/2022 - 01/2015
12	Pharmaceutical PreparationsIBA 02/2022 - 09/2001
11	Monoclonal AntibodiesIBA 08/2019 - 01/2009
10	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 12/2011
10	Gemcitabine FDA Link 01/2020 - 02/2005
9	Cetuximab (Erbitux)FDA Link 09/2015 - 01/2009
8	Capecitabine (Xeloda)FDA Link 01/2022 - 06/2003
8	ErbB Receptors (EGF Receptor)IBA 08/2019 - 01/2009
7	CytokinesIBA 08/2021 - 01/2018
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2019 - 04/2012
6	Immune Checkpoint ProteinsIBA 05/2022 - 04/2019
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2005
5	VaccinesIBA 01/2022 - 01/2020
4	RNA (Ribonucleic Acid)IBA 02/2022 - 08/2019
4	B7-H1 AntigenIBA 01/2021 - 07/2020
4	Paclitaxel (Taxol)FDA LinkGeneric 02/2020 - 02/2005
4	Panitumumab (Vectibix)FDA Link 09/2015 - 01/2009
3	CateninsIBA 07/2022 - 10/2017
3	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 01/2015
3	Docetaxel (Taxotere)FDA Link 01/2022 - 01/2003
3	Tyrosine Kinase InhibitorsIBA 11/2021 - 01/2011
3	durvalumabIBA 06/2021 - 06/2020
3	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 01/2015
3	PlatinumIBA 12/2020 - 12/2005
3	Tumor Biomarkers (Tumor Markers)IBA 09/2020 - 01/2014
3	Angiogenesis InhibitorsIBA 02/2020 - 03/2016
3	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 09/2012
3	folfirinoxIBA 01/2020 - 11/2013
3	Phosphotransferases (Kinase)IBA 10/2019 - 01/2011
3	ParaffinIBA 08/2019 - 02/2013
3	130-nm albumin-bound paclitaxelIBA 05/2019 - 01/2014
3	Bevacizumab (Avastin)FDA Link 07/2016 - 02/2015
3	Vinorelbine (Navelbine)FDA LinkGeneric 07/2015 - 06/2003
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2022 - 04/2013
2	AntigensIBA 01/2022 - 07/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 08/2019
2	Oncogene Proteins (Oncogene Protein)IBA 11/2021 - 04/2020
2	LigandsIBA 11/2021 - 06/2020
2	mesoglycanIBA 09/2021 - 01/2021
2	tremelimumabIBA 06/2021 - 06/2020
2	ArginaseIBA 03/2021 - 01/2020
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 06/2020
2	VenomsIBA 11/2020 - 11/2020
2	Cytotoxins (Cytolysins)IBA 11/2020 - 11/2020
2	Nucleic AcidsIBA 10/2020 - 05/2020
2	NivolumabIBA 07/2020 - 06/2020
2	avelumabIBA 07/2020 - 06/2020
2	pembrolizumabIBA 07/2020 - 06/2020
2	atezolizumabIBA 07/2020 - 06/2020
2	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 12/2011
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 09/2014
2	AlbuminsIBA 10/2019 - 01/2014
2	Gefitinib (Iressa)FDA Link 05/2019 - 09/2013

Therapy/Procedure

69	Therapeutics 05/2022 - 09/2001
51	Drug Therapy (Chemotherapy) 12/2022 - 06/2003
23	Immunotherapy 06/2022 - 10/2016
9	Radiotherapy 05/2022 - 02/2010
4	Precision Medicine 02/2022 - 01/2017
4	Chemoradiotherapy 01/2019 - 02/2010
3	Neoadjuvant Therapy 01/2022 - 09/2001